Follow up about two cases report after posaconazole therapy

Main Article Content



Zygomycosis is a rare opportunistic fungal infection, that often complicates patients with uncontrolled Diabetes Mellitus, primary and acquired immunodeficiencies as defects of the cell-mediated immunity, myelodisplastic syndrome, hematological malignancies undergoing chemotherapy , HIV and long term therapy with steroid [1]. Mortality rate of these patient is very high, until 85% [2].

The causative organism is an aerobic saprophytic fungus, releasing spores, belonging to the order of Mucorales of the class Zygomycetes [3].  Inhalation and direct contamination of skin lesions are the major causes of infection, so the sporangiospores can migrate up to the  lungs, nasal cavity and paranasal sinuses, gut and cutaneous tissues causing primary infection, hyphae invade vassels producing thrombi. Rhinocerebral Zygomycosis occurs with cranial nerve palsies, eye proptosis, pain and often blindness. Zygomicetes can invade central nervous system (CNS) from paranasal sinuses or remote site of infecton [1].

This life-threatening infection could be defeat through early detection, surgical excision and appropriate debridement, aggressive antifungal therapy, and control of risk factors, like diabetes mellitus like in our cases.

We reported the follow up after long term therapy with Posaconazole in two Italian girls with Diabetes Mellitus Type 1 previously published [1,4].

Article Details

How to Cite
TARANI, LUIGI. Follow up about two cases report after posaconazole therapy. Medical Research Archives, [S.l.], v. 4, n. 5, sep. 2016. ISSN 2375-1924. Available at: <>. Date accessed: 26 sep. 2023.
Rhino cerebral Mucormycosis; Posaconazole therapy; Pediatric
Case Reports


1.Di Coste et al.: Rhinocerebral zygomicosis with pnsinusitis in a 14- year- old girl with type 1 diabetes: a case report and review of the literature. Italian Journal of Pediatrics 2013 39:77.

2.Palejwala SK et al.: An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormicosis. Surgical Neurology International. 2016 May 25;7:61. doi:10.4103/2152-7806.182964.

3.M. Chayakulkeeree et al.: Zigomycosis: the re-emerging fungal infection. Eur JClin Microbiolo Infect Dis (2006) 25: 215-229. DOI 10.1007/s10096-006-0107-1

4.Tarani et al.: Long term posaconazole treatment and follow up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatric Diabetes 2009: 10: 289-293. DOI 10.1111lj.1399-5448.2008.00465.x

5.A. Alastruey-Izquierdo et al. In vitro activity of antifungals against Zygomicetes. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:71-6. doi: 10.1111/j.1469-0691.2009.02984.x. Review.

6.Schiller et al. Posaconazole: an extended spectrum triazole antifungal agent. Clin Ther 2007,29(9):1862-86

7.Peyton LR et al.: Triazole antifungals:a review. Drugs Today (Barc). 2015 Dec;51(12):705-18. doi: 10.1358/dot.2015.51.12.2421058. Review

8.Herbrecht R. et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.

9.Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayll Univ Med Cent)2007: 20:188-196

10.Kursun E et al. Evaluation of 28 cases of mucormycosis. Mycoses. 2015 Feb;58(2):82-7. doi: 10.1111/myc.12278. Epub 2015 Jan 15.

11.Manesh A et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016 Jul 22. doi: 10.1111/myc.12529.

12.Cornely OA et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014 Apr;20 Suppl 3:5-26. doi: 10.1111/1469-0691.12371